The Latest in Clostridioides difficile Research and News

November is Clostridioides difficile awareness month. Here is a rundown on the latest news and research happening with this infection.

Two Years After its FDA Approval, Rebyota Continues to Show Efficacy and Safety

Paul Feuerstadt, MD, FACG, AGAF, discusses what the data says as well as offers insights about what patients can expect and medical peer-to-peer information about the procedure.

Due to FDA Policy Change, Fecal Microbiota Transplants Are in a Tenuous Position

The country’s largest fecal distributor, OpenBiome, could be prevented from offering the product next year if the FDA does not approve the product used for fecal microbiota transplants to treat fulminant C difficile.

Progress in Reducing C difficile Infections Highlights Key Achievements During C diff Awareness Month
In recognition of C difficile awareness month this November, the CDC's 2023 HAI Progress Report highlights continued progress in reducing CDIs across US healthcare settings.

Oral Vancomycin Reduces CDI by 64% in Stem Cell Transplant Patients

Reduction of in-hospital rate of C difficile infection from 11% to 4%, with no increased risk of infection following treatment.

Identifying Risk Factors for Reduced Vancomycin Susceptibility in Clostridioides difficile Infections

An analysis revealed that 29% exhibited reduced susceptibility to reduced vancomycin, underscoring the importance of enhanced monitoring of these strains to inform antibiotic prescribing practices